Reddit Posts
420 Alert🚨US cannabis rescheduling imminent
420 Alert: Weed stocks are back. And they want to apologize for last time.
Cannabis Investing Network: #179 - Q2 Financial Review of the Big 5 MSOs (ft. Nick Gastevich aka CannaVestments) on Apple Podcasts
Historic Marijuana Milestone: Georgia First In Nation Where Hundreds Of Drug Stores Will Sell Medical Cannabis - CVS Health (NYSE:CVS), TRULIEVE CANNABIS CORP by Trulieve Cannabis Corporation (OTC:TCNNF)
Twitter is Helping the Cannabis Industry Grow LIVE TODAY!!
High Valuations? Exploring P/B Ratios in the Cannabis Sector
Beyond the Smoke: Unraveling Price-to-Book Ratios of Cannabis Stocks
MSOS ETF and underlying free cash flow changes with Schedule 3 Cannabis.
How exactly the reclassification of Marijuana will affect marijuana companies/stocks
FYI: Seabreeze Capital's Dougie Kass added to his cannabis longs in June
Penny stock goldmines: 4 Jewels to grab for big returns by 2024
USA Cannabis stocks are about to LIGHT UP - $MSOS (USA Cannabis ETF)🌿🔥 😎
USA Cannabis stocks are about to LIGHT UP - $MSOS (USA Cannabis ETF)🌿🔥 😎
Q2 Sales Data Headset - never mind safe lets focus on Sales
Ron DeSantis And Florida Lawmakers Estimate Legal Weed Will Generate At Least $500M In Tax Revenue - Trulieve Cannabis (OTC:TCNNF)
Florida Attorney General Attacks Trulieve CEO - TCNNF
Over 100 Pharmacies Line Up To Sell Medical Marijuana In Georgia According To New Rules - Trulieve Cannabis (OTC:TCNNF)
Florida Supreme Court Gives AG Moody 2 More Weeks To File Briefs In Marijuana Legalization Ballot Challenge And Gives Her A Warning! -TCNNF
Marijuana banking bill heads to Senate Banking Committee - MSOS TCNNF MJ
Optimism Runs High As Marijuana Banking Bill Heads To Senate For Consideration Tomorrow
Trulieve TCNNF: a deep value Tier 1 US MSOS that dominates Florida and is rapidly growing in other States that'll benefit from SAFE Banking
Breaking News: SAFEBANKING Hearing to take place this Thursday May 11th! US MSOS will easily pop 50%-100% GTBIF TCNNF MSOS
Safe Banking Act Timeline and Implications
Congress poised to pass marijuana banking reform in lame duck
A Guy models out Trulieve (TCNNF) Stock AND sees big upside - good analysis and DCF with modest growth rate
Fidelity Just Closed My Account Without Warning, Who Should I Transfer My Cannabis Stocks To?
With legalization on the horizon, what's the best play to maximize profits.?
The SAFE Banking Act is likely up for vote TODAY in the House.
WHY oh why Down 30% since my first OTC investment last year. I’ve got everything from Planet 13 to TCNNF. 🤦♀️
US Cannabis MJ-largest short positions on the CSE- Short Rally Underway!!
Get your heads out of your asses and take a look at this stock $TCNNF
Keynote: Trulieve (OTCMKTS: TCNNF) | Benzinga Cannabis Capital Conference | October 2021
Mentions
[NASA will roll Artemis 2 moon rocket out to the launch pad on March 19](https://www.space.com/space-exploration/artemis/nasa-will-roll-artemis-2-moon-rocket-back-to-the-launch-pad-on-march-20) This will be the year of the Space Mob! I saw a Starlink commercial on TV the other day. ASTS, PL, ONDS, UMAC, AMPX, RKLB, TSSI, FLY, JOBY, just check them out. SpaceX ipo coming, this may hurt some of these stocks or help, I'm undecided. \---- 4/20 bet plus rescheduling cannabis TCNNF. I visited today and it's legit, clean, good knowledgeable staff. They are a solid player in the FL landscape. In for 100 shares.
More DK buys: Added to ([**MSOS**](https://www.thestreet.com/quote/MSOS)) $3.75 and ([**TCNNF**](https://www.thestreet.com/quote/TCNNF)) $6.16.
I gave up, I am down to just TCNNF and GTBIF and at the very least TCNNF is on a ticking clock til the end of April, then its getting cleared from the account. I check here once every couple weeks and its always this same ghost town. 38 comments at almost 2PM. What a disaster. Anyone who still has hope here must just be doing opioids and living in a dream cloud, not cannabis. As usual there is just always something more important going on, Epstine shit still not resolved, now war in Iran. This sector is forever the carrot. And really 98% of these companies financials are trash, the economy is doing terrible, the growth in these names is pathetic. There is basically no reason to invest in this sector whatsoever other than the lottery ticket that is "reform".
Doug is still pumping. "We have been aggressively buying $MSOS $GLASF $TCNNF $GTBIF and $TSNDF" "We expect rescheduling to be announced imminently. Cannabis investors have been taken to the woodshed and beat up over the last five years and even recently (despite the initial statement by @potus that he is recommending rescheduling)." I think his "confusion" at why anyone would sell on EO day is laughable considering he was first in line to sell, and was dunking on Twitter longs. For anyone new, Doug is a whale who periodically pumps and dumps this sector.
I dumped all my CRON, finally dumped IIPR: both dead money. CRON: never moves, allergic to $3, even if we hit a hype cycle its going to under perform. IIPR: ridiculous dividend but the share price just keeps getting ripped into, false gains. Next up TCNNF: far to much debt, far to much risk tied to Florida exposure/vote, huge tax liability, stalled growth. Looking to exit entire position by the end of April, hoping to sell half at $9 other at $10 from some random hype cycle but if nothing by the end of April... I'm out. That'll leave me just GTBIF and despite their resilience... they can't do it alone, so sick of "the best" being dragged down by a sector that has so many problems. I'll move to the "best" in another sector and just walk away from this forever. I haven't decided my move yet for GTBIF... but its a ticking clock.
Swapped some TCNNF for VRNO. Seems like a decent bet with Virginia coming online this year
From the top of my head a quick list of companies based on cash flow, a solid balance sheet, organic revenue growth, no excessive dilution: Canada: HITI, VFF, Rubicon, Decibel, perhaps Auxly US: GTBIF, TCNNF, perhaps Cresco. There's almost certainly more but these are the ones i have some experience with analyzing. Im not well known wirh US MSOS. Avoid the meme names like CGC, TLRY like the plague.
I don’t know if this was a glitch, last night TCNNF went down to .0001 a share. Shortly after went up to over $60 a share. This was also Schwab.
She would have to bounce a hundred for me to break even. Fortunately I only lost 1k in a wash sale. I put all my power into GTI & TCNNF
I went back and studied the timing of major announcements coming out of the Trump administration, and the pattern is hard to ignore. The executive order was announced on the exact same day Congress mandated the release of the Epstein files, December 19th. We already know there are millions of pages still under review, and the administration has openly admitted it needs “a few more weeks” for redactions. That delay isn’t random. Once the final tranche of documents is released, I expect Trump to immediately move to formalize Schedule III into law, not just as policy, but as a media counterweight. This is how narratives get buried. Big revelations are rarely allowed to stand alone. Notice how Nigeria was bombed on Christmas Day over oil, another example of how global events are conveniently timed to dominate headlines and redirect attention. Markets react faster than the public connects dots. On that basis, I loaded up on GTI and TCNNF.
TCNNF (Trulieve) upon Bondi finalizing cannabis rescheduling and possible rec use in Florida. 🚀easy 5 bagger.
Today will be interesting. MSOX to maximize profit but risk volatility, MSOS=less volatility but less profit. Or you could invest in individual companies like TCNNF or others. CNBS is also a good ETF for MSO's but has a much higher entry cost but i do like the MSO positions they hold. MSO=Multi State Operator
280e tax burden GONE, no longer taxed as a schedule 1 product. Medical Research will explode and medical Cannabis Companies will provide the plants for that research. Trulieve AKA TCNNF already work with several Universities. International commerce is now a real option for exports. Market manipulators might try to trigger stop losses but i doubt that will effect long term investments.
It's not about the IRS "erasing" what they already have; it's about the billions they haven't collected yet. The top MSOs like $TCNNF and $GTBIF are currently carrying massive "Uncertain Tax Positions" on their balance sheets—this is cash they’ve set aside but haven't actually paid to the IRS while they challenge 280E. Once Schedule III is final, those liabilities can be reversed, instantly padding the bottom line. Plus, Trulieve already proved it's possible—they actually got $113M in physical refund checks from the IRS for 2019-2021 by filing "protective claims." Rescheduling makes those claims 10x stronger. The IRS isn't being "nice"; they're being forced to follow a tax code that legally can't apply to Schedule III drugs.
It's not about the IRS "erasing" what they already have; it's about the billions they haven't collected yet. The top MSOs like $TCNNF and $GTBIF are currently carrying massive "Uncertain Tax Positions" on their balance sheets—this is cash they’ve set aside but haven't actually paid to the IRS while they challenge 280E. Once Schedule III is final, those liabilities can be reversed, instantly padding the bottom line. Plus, Trulieve already proved it's possible—they actually got $113M in physical refund checks from the IRS for 2019-2021 by filing "protective claims." Rescheduling makes those claims 10x stronger. The IRS isn't being "nice"; they're being forced to follow a tax code that legally can't apply to Schedule III drugs.
People see a 27% drop and assume the news was bad, but they’re missing the forest for the trees. This is a classic 'sell the news' event after a 50% run-up on rumors. The market is panicking a little because it didn't get instant 'Full Legalization,' but **the smart money knows that tripling your profit by fixing the tax code is worth way more than being able to take a credit card at the register.** For the first time in a decade, $TCNNF and the other MSOs aren't just 'selling weed'... they are finally allowed to **keep the money** they make. The prohibition tax is dead, the competition is getting outlawed, and the cash flow is about to explode. I'll take that fundamental reality over a one-day trading glitch any day.
I grabbed some TCNNF after it dumped 15%? and still managed to lose 10%. Absolutely unhinged price action.
CBD hemp good news : RYM down Medical good news: TCNNF down GTI goes up the least, falls as hard with the rest
Everybody invest in Oklahoma right now, holy money maker. I know a few places that are great, but avoid investing in CURLF and TCNNF, they're not likely to get past state legislatures for a few years and start producing. Oklahoma has a moratorium on new growers until August, so the big players here are the ones that are likely to stay on top. Invest in towns like Noble, or Moore, or Norman. There's a lot of industrial professors here and growers a few miles away, we grow 32x the amount of weed needed for the state consumption and are absolutely going to explode when it's allowed between states
The fact that MSOS/TCNNF are down \~12% and Tilray is up 7% goes to show how much the lack of marijuana, and the strong presence of CBD references, impacts trading.
With 280E gone, GTBIF and TCNNF are trading at 7.0x forward earnings. Deep value territory. Lost a bunch on my FOMO buys today, but very positive about future prospects.
The Bread Guy 🤝 TCNNF Moon Trulieve shareholders 🤝
Today is cannabis day as an executive order is finally signed to move it to schedule 3. GTBIF , MSOS, are still historically low, not even back to pre-November levels. I expect a moonshot today. I’m in MSOS, MSOX, TCNNF and GTBIF
I've been waiting for this for a while - I bought my weed stocks mainly in May / June, earlier in the year. These stocks have been absolutely crushed, and weed stocks seem to go in God-mode rallies every number of years (i.e. 2018, end of 2020, beg of 2021), where the underlying stocks can sometimes 5-10X (perhaps life changing money), and I had a feeling that Trump would eventually reschedule. Also, the latest hemp ban is good for the industry, because companies have been selling hemp with tons of THC for years, so that was taking away business from regular cannabis co's. We still have banking reform that can happen (i.e. being able to use CC to buy weed, and allowing these companies to be able to do business / get loans from major banks), and then the really big one, uplisting onto NYSE / Nasdaq. A lot of people like to buy TLRY, but they don't even benefit from US federal reform. The beneficiaries are the US companies which can only be found on OTC (i.e. GTBIF, TCNNF, VRNO, CURLF, etc.). All in all, I'm roughly around 2-3X on my buys, and am holding longer for more.
This post made me do a deep dive into how sketchy TCNNF is playing these 280e taxes. Kim better remember the golden bong tomorrow.
https://www.reddit.com/r/weedstocks/comments/1potoc2/daily_discussion_thread_december_17_2025/nuiksxe/ Not that surprising when Dan spends 3x as much on CURLF and more than double on TCNNF than GTBIF.
Held up much better yes. but has lagged every single move. TCNNF is nearly the same MC and CURLF is 50% higher. There is no reason GTBIF shouldn't have a value premium SIGNIFICANTLY higher than CURLF and definitely much higher than TCNNF when their financials are in a complete league of their own. There is nothing fairly valued about a company trading at a 50% discount to a less than 10%? revenue deficit while having 40% less debt to assets.
You need to invest in American Cannabis. GTIBF, CURLF, TCNNF, VRNO, CRBLF or the ETF MSOS
This always happens with GTBIF, we are trailing TCNNF, should be telling. The price correction will happen but not until we get reform and real money entering the sector. Be patient we know the truth
I purchased Canopy (CGC) a few days ago based on the news regarding possible reclassification. Check out CURLF as well. The others I can think of (TCNNF, ACB) are not penny stocks but I'm sure there are more that are.
If you are looking for weed play, consider GTBIF or TCNNF, or just MSOS. Don't fall for trash like TLRY. Monday could be sell the news tho, unless something unexpected in the EO
Add Trulieve, $TCNNF to the upside. I don’t think Monday will be red, as too much pent up buying demand.
TCNNF is the real beast. Up 66% on 2m shares. Once they uplist this will be loco.
All joking aside then, who else do you think is making a profit AND doesn't have a ton in back taxes? I used to think TCNNF and VRNO were in this club, but I don't think it's the case any longer.
Damn, TCNNF, trulieve up 65%, gotta love a good reclassification of Mary Jane...
GTBIF and TCNNF trading in lockstep share price is just so odd. Seen it to many times that they're kept to the penny of each other.
**📊 280E Tax Relief – Cannabis MSO Estimates (Rescheduling → Schedule III)** Rescheduling could remove 280E, letting companies deduct normal expenses. Analyst research (Zuanic, Water Tower, Whitney) shows potential annual savings: |Company|2025 Revenue|Est. 280E Savings| |:-|:-|:-| |Curaleaf (CURLF)|$1.3–1.5B|$150–200M| |Trulieve (TCNNF)|$1.1–1.3B|$120–180M| |Green Thumb (GTBIF)|$1.0–1.2B|$100–150M| |Verano (VRNOF)|$900–1,000M|$80–120M| |Cresco (CRLBF)|$800–900M|$70–100M| |Jushi (JUSHF)|$250–500M|Up to \~$514M| |Cannabist / Columbia Care|$300–360M|$35–50M| |Planet 13 (PLNHF)|$95–110M|$9–15M| |MariMed (MRMD)|$150–180M|$15–25M| **Takeaways:** * Total U.S. MSO tax savings could reach **$2–3B+ annually**. * Largest absolute beneficiaries: Curaleaf, Trulieve, Green Thumb. * High % upside: Jushi, Planet 13, MariMed. * Retroactive refunds are speculative; cash depends on DEA/HHS action & IRS guidance.
Lawmakers could force the DEA to remove cannabis from the Schedule-1 list, with a 90-day time limit, to allow the FDA to study it for medical value so insurance companies can help patients obtain it at hospitals and pharmacies such as Walgreens, Costco, or CVS provided by existing multi-state operators such as MRMD (Marimed Inc.), CURLF (Curaleaf), TCNNF (Trulieve) and many other multi-state operators.
Lawmakers could force the DEA to remove cannabis from the Schedule-1 list, with a 90-day time limit, to allow the FDA to study it for medical value so insurance companies can help patients obtain it at hospitals and pharmacies such as Walgreens, Costco, or CVS provided by existing multi-state operators such as MRMD (Marimed Inc.), CURLF (Curaleaf), TCNNF (Trulieve) and many other multi-state operators.
Congress can pass a simple statutory directive ordering the DEA to remove cannabis from Schedule I within a fixed window, and because scheduling authority ultimately comes from the Controlled Substances Act, lawmakers can override the agency with a single amendment that bypasses the slow administrative process. Once removed from Schedule I, the FDA immediately gains freedom to run full clinical evaluations, allowing cannabis to enter the same medical review pipeline used for any other therapeutic, which reshapes how investors view long-term regulatory clarity. A congressional mandate would also trigger automatic coordination between the DEA, FDA, and HHS, because descheduling forces these agencies into a compliance posture rather than a discretionary one, eliminating the political bottleneck that normally stalls progress. That fast alignment is exactly what markets tend to reward, since it takes the uncertainty premium off U.S. cannabis operators and opens the door for mainstream institutions that have been waiting for a clear federal rule. Once the FDA enters the picture with formal pathways, insurers can legally reimburse cannabis-based treatments through standard medical benefit structures, and hospitals or major retail pharmacies can dispense products sourced from established operators. That shift converts cannabis from a fragmented state-only model into a federal healthcare product, positioning companies like MRMD, CURLF, and TCNNF to plug directly into the national distribution chains they’ve been structurally built for. Congress can also attach descheduling to a broader health or appropriations bill, a tactic used constantly to move policy changes without relying on standalone votes. That approach makes passage much easier, because it folds cannabis into routine legislative cycles, sidestepping headline political fights and letting the reform ride through on a must-pass vehicle—something markets interpret as near-guaranteed execution once language is included. All of this creates a straightforward pathway: congressional directive → DEA compliance → FDA evaluation → insurance coverage → mainstream pharmacy distribution → national scale for operators. For lawmakers, it’s one of the cleanest federal reforms available; for the sector, it’s a regulatory unlock that allows U.S. cannabis stocks to function like normal consumer-health companies instead of siloed state-restricted plays.
Lawmakers could force the DEA to remove cannabis from the Schedule-1 list, with a 90-day time limit, to allow the FDA to study it for medical value so insurance companies can help patients obtain it at hospitals and pharmacies such as Walgreens, Costco, or CVS provided by existing multi-state operators such as MRMD (Marimed Inc.), CURLF (Curaleaf), TCNNF (Trulieve) and many other multi-state operators.
Congress could require the DEA to move cannabis out of Schedule I within 90 days, instantly opening the door for a full scientific review. Once it’s descheduled, the FDA would run a complete evaluation—clinical data, therapeutic applications, dosing ranges, safety profiles, manufacturing standards, purity requirements, and how cannabis fits into existing classes of regulated medicines. HHS would take those findings and issue a formal medical determination, creating a nationally recognized foundation for regulated therapeutic use. That shift unlocks insurance coverage because FDA and HHS recognition allows CMS and private insurers to treat cannabis like any other approved treatment. Hospitals, integrated health networks, and major pharmacy chains could then stock and dispense standardized, FDA-compliant formulations. Operators like MRMD, CURLF, and TCNNF—already functioning in tightly regulated state systems—could transition into federally compliant production, scaling supply across state lines and eventually into international medical markets under unified standards. The sequence becomes: Congress directs DEA → DEA deschedules → FDA defines medical standards → HHS certifies medical use → insurers reimburse → pharmacies and hospitals dispense → regulated producers supply a national and global market.
It's largely due to MSOS bias. The ETF has way too much power over how flows into the sector are divvied up. To give you an idea, YTD through Sept 30th, MSOS bought the following ($ cost is rough estimate based on avg price, but share count is real): 27,763,839 shares of $CURLF: ~$58,000,000 USD 6,664,172 shares of $TCNNF: ~$36,000,000 USD 20,667,716 shares of $TSNDF: ~$16,000,000 USD 2,308,623 shares of $GLASF: ~$14,000,000 USD 15,286,863 shares of $CRLBF: ~$15,000,000 USD 13,150,626 shares of $VRNOF: ~$13,000,000 USD And finally, 1,160,328 shares of $GTBIF: ~$5,800,000 USD Dan, $MSOS ETF manager, despises Ben Kovler and GTI, and prefers to buy just about any other weed stock other than GTI for that reason. Fundamentals be damned
Lawmakers could order the DEA to take cannabis off Schedule I within 90 days, clearing the way for FDA review and opening the door for insurance-covered access through hospitals and major pharmacies like Walgreens, Costco, and CVS, supplied by existing MSOs such as MRMD, CURLF, TCNNF, and others.
huge debt, very unlikely to see 280e reform this year, TCNNF taking it in the butt too.
MRMD could push higher with volume and news about Medical Cannabis. Lawmakers could force the DEA to remove cannabis from the Schedule-1 list, with a 90-day time limit, to allow the FDA to study it for medical value so insurance companies can help patients obtain it at hospitals and pharmacies such as Walgreens, Costco, or CVS provided by existing multi-state operators such as MRMD (Marimed Inc.), CURLF (Curaleaf), TCNNF (Trulieve) and many other multi-state operators.
Lawmakers could force the DEA to remove cannabis from the Schedule-1 list, with a 90-day time limit, to allow the FDA to study it for medical value so insurance companies can help patients obtain it at hospitals and pharmacies such as Walgreens, Costco, or CVS provided by existing multi-state operators such as MRMD (Marimed Inc.), CURLF (Curaleaf), TCNNF (Trulieve) and many other multi-state operators.
I bought 50,000 of MRMD bc lawmakers could force the DEA to remove cannabis from the Schedule-1 list, with a 90-day time limit, to allow the FDA to study it for medical value so insurance companies can help patients obtain it at hospitals and pharmacies such as Walgreens, Costco, or CVS provided by existing multi-state operators such as MRMD (Marimed Inc.), CURLF (Curaleaf), TCNNF (Trulieve) and many other multi-state operators.
Lawmakers could force the DEA to remove cannabis from the Schedule-1 list, with a 90-day time limit, to allow the FDA to study it for medical value so insurance companies can help patients obtain it at hospitals and pharmacies such as Walgreens, Costco, or CVS provided by existing multi-state operators such as MRMD (Marimed Inc.), CURLF (Curaleaf), TCNNF (Trulieve) and many other multi-state operators.
Nah man GTBIF is probably the most solid of the bunch. Im in on TCNNF only because they are massive. Kim Rivers kissed the ring its gunna happen. Good luck!
The TCNNF and GTBIF charts are basically identical, share price and movements for the last 3 months. It means nothing, but its just really strange to see.
1. What Schedule III Reclassification Actually Does If cannabis moves from Schedule I → Schedule III, it means: • The U.S. government formally recognizes medical use. • Cannabis is no longer in the same class as heroin or LSD, but with drugs like Tylenol with codeine, testosterone, and ketamine. • The DEA and FDA can regulate it as a controlled, but prescribable substance. That change has massive secondary effects on financial and regulatory systems — especially custody and uplisting. ⸻ 💰 2. Why Cannabis Stocks Are Currently Locked Out of Major Exchanges Right now, U.S. cannabis companies like Trulieve (TCNNF) and Green Thumb (GTBIF) can’t list on the NYSE or NASDAQ because: • Those exchanges are regulated by the SEC and must comply with federal law. • Since cannabis is federally illegal (Schedule I), listing them would mean a federal crime is being facilitated (distribution of a controlled substance). • Similarly, U.S. banks and custodians (like JPMorgan or Goldman) can’t hold or clear trades in cannabis-touching companies, since that’s aiding an illegal enterprise under federal law. That’s why U.S. multi-state operators (MSOs) trade only on Canadian exchanges (CSE) or OTC markets under “F” tickers — and that’s why liquidity is so poor. ⸻ 🏛️ 3. How Schedule III Fixes That Problem If cannabis becomes Schedule III, then: • It is no longer federally illegal for companies to manufacture, distribute, or sell it under DEA/FDA oversight. • The Controlled Substances Act (CSA) would no longer prohibit these companies’ core business. • Therefore, U.S. cannabis companies would no longer be “trafficking in a Schedule I substance.” That legal distinction allows: • NYSE and NASDAQ to legally uplist U.S. cannabis stocks (since their business is no longer federally illegal). • Prime brokers, custodians, and clearing firms (like Pershing, Fidelity, JPMorgan) to hold, clear, and custody cannabis securities safely. • Institutional investors (mutual funds, ETFs, pensions) to finally participate. Essentially, the federal legal barrier disappears. ⸻ 📈 4. Key Consequences Once That Happens If Schedule III becomes official: 1. MSOs can uplist — TCNNF → TLVF (or similar) on NASDAQ. 2. Custody opens up — brokers like Fidelity or TD can hold shares directly rather than via foreign intermediaries. 3. Liquidity soars — volume increases, bid/ask spreads tighten. 4. Institutional money enters — funds and ETFs that currently can’t touch these names flood in. 5. Valuations normalize — MSOs rerate closer to mainstream consumer/healthcare stocks (think 5–10× EBITDA instead of 3×). ⸻ ⚠️ 5. Important Caveats • Schedule III doesn’t automatically mean dispensaries can sell Schedule III products overnight — DEA and FDA will set frameworks. • Adult-use (recreational) cannabis may still operate in a gray zone until Congress or DOJ guidance clarifies it. • Uplisting won’t happen immediately — exchanges will likely wait for formal DEA final rule + DOJ guidance confirming that cannabis businesses are federally compliant. • The SAFE Banking Act could still accelerate financial normalization in the meantime.
Happy I stuck to my guns, sold profit last week predicating price suppression for massive OPEX today. Added 5 min before the close to [$GTBIF](https://x.com/search?q=%24GTBIF&src=cashtag_click) [$TCNNF](https://x.com/search?q=%24TCNNF&src=cashtag_click). New position in [$CURLF](https://x.com/search?q=%24CURLF&src=cashtag_click). [$MSOS](https://x.com/search?q=%24MSOS&src=cashtag_click) and the underlying continue to be predictable. Hoping for news soon, low options volume moving into Nov. I think there's room to run. Happy Friday.
Ok. Listen, posting about MSOS OPEX and TCNNF after Friday’s close doesn’t help anyone trade—it’s just hindsight. No entry price or why you sold makes it feel like a brag, not advice. Newbies like me can’t learn without those details and pros don't even read this forum . Maybe to check for hype once in a while. Forums work when you share real trade setups before they happen, like: what signals to watch. Drop that next time so we can actually use it.
Oct 17th massive opex open interest on MSOS. Overall market pullback, expecting more blood this coming week with Trump tariff threats against China. With no news, expect MSOS and the basket to bleed further with the overall market or trade sideways into Friday close so MM’s can expire those calls worthless. Sold a good chunk of TCNNF this week, luckily. Sitting on cash and will be looking to deploy aggressively next week if opportunity presents. More so aiming for EOD Friday. Hopefully we get news soon! 🍀
Trimmed some gold and silver and UNH early and took advantage of the sales late today -- CNC PLTR MOS TCNNF.
I bought 2k more shares of Trulieve at $7.85 USD. I now own 12k shares at an average of $5.10 USD, so averaging up basically. I only own GTBIF and TCNNF for weed stocks at the moment. The rest of my portfolio is index funds.
They always are. Buy American weed companies $TCNNF
Any ideas why TCNNF is still up 16%?
We're already past 5 million in $ volume traded today on both GTBIF and TCNNF
I'm seeing GTBIF and TCNNF already having traded more than their 90 avg volume in the first hour of trading. Looks decent to me
How can one side of their mouth sore Schedule 1 while the other is signaling Schedule 3? I have a whale sized position in TCNNF and have no concerns. If Trump fumbles the issue, eventually the house of redder madness will crumble. Our day is coming! The question is whether it will be a few weeks, midterms or years ahead.
Incase anyone is curious I asked Grok 4 Expert why the next two largest MSOs haven’t uplisted from the CSE to the TSX: Trulieve Cannabis (CSE: TRUL; OTC: TCNNF) and Green Thumb Industries (CSE: GTII; OTC: GTBIF) have not uplisted to the Toronto Stock Exchange (TSX) primarily due to strategic priorities, regulatory complexities, and perceived limited benefits compared to potential future U.S. exchange listings. 97 107 108 Both companies, as U.S.-based multistate operators (MSOs) in the cannabis sector, face unique challenges stemming from federal illegality in the U.S., which complicates listings on major exchanges. Key Reasons: • Focus on Potential U.S. Exchange Uplisting: Many MSOs, including Trulieve and Green Thumb, are prioritizing federal cannabis rescheduling (e.g., moving to Schedule III), which could eliminate punitive 280E taxes and enable direct listings on U.S. exchanges like NASDAQ or NYSE. 7 30 76 62 This would offer greater liquidity, higher valuations, and broader institutional access than the TSX. Rescheduling progress (e.g., HHS recommendations and ongoing DEA reviews) has fueled optimism, making a TSX move seem like an unnecessary interim step. 96 94 For instance, Trulieve filed a shelf registration in June 2025 with no immediate plans for offerings, signaling preparation for U.S. opportunities rather than TSX. 83 • Higher Costs and Complexity of TSX Uplisting: Listing on the TSX is more expensive and rigorous than remaining on the Canadian Securities Exchange (CSE), where both companies currently trade. 107 It often requires raising capital (e.g., Curaleaf raised CA$16 million in 2023 to meet TSX float requirements) and complex restructuring, such as ring-fencing U.S. plant-touching assets to comply with legal concerns. 79 81 107 This could involve dilution, which both companies may want to avoid—Green Thumb announced a $50 million share repurchase program in 2024, focusing on returning value to shareholders instead. 73 Auditor sign-off on consolidated financials including U.S. operations remains uncertain due to federal risks. 107 • Limited Perceived Benefits: While the TSX offers better visibility and potential index inclusion (e.g., S&P/TSX Composite), experiences like Curaleaf’s suggest it may not significantly boost institutional investment or valuations due to share structures and ongoing U.S. federal stigma. 2 105 108 98 Trulieve and Green Thumb, with strong operational focus (e.g., expansions in Florida and Ohio), may see staying on CSE/OTC as sufficient for now, especially with comparable market caps to Curaleaf (~C$2 billion each). 12 6 • Market and Regulatory Caution: The TSX has been receptive to cannabis firms, but U.S. MSOs must navigate TMX Group policies on U.S. operations. 80 1 61 With events like Florida’s failed adult-use legalization in 2024 impacting sector sentiment, companies like Trulieve (heavily Florida-exposed) are prioritizing cash flow and operations over exchange upgrades. 4 95 Overall, while not explicitly stated by the companies, analyst commentary and industry trends indicate these MSOs view TSX uplisting as a lower-priority move amid hopes for U.S. reforms. 97 102 If rescheduling stalls, they could reconsider, as seen with Curaleaf in 2023. 86
"For TCNNF, paying 280E-related tax liabilities for prior periods would likely not be highly damaging due to its financial scale, ability to defer payments through legal procedures (e.g., refund claims, audits, or litigation), and strong market position. A liability in the tens of millions would be manageable within its $1.13 billion revenue and $273 million EBITDA, and legal deferrals could mitigate cash flow impacts. Rescheduling to Schedule III in 2025 would eliminate future 280E burdens, further supporting TCNNF’s growth. While Trump could push for retroactive relief to erase past liabilities, benefiting TCNNF significantly, the company’s progress is unlikely to be derailed even without such relief. TCNNF should continue leveraging tax advisors to maximize deferrals and monitor legislative developments for potential refund opportunities."
Trump’s pro-rescheduling stance and pro-business rhetoric suggest he could support legislation providing retroactive relief from 280E taxes, recognizing the damage it has caused to companies like TCNNF. His influence could sway Republican lawmakers to back bills like the Small Business Tax Equity Act or the STATES Act, amended to include refund provisions.
Tilray is a money dilution machine, good short term play. Invest in real companies like $GTBIF $TCNNF
Rather buy solid companies like $GTBIF $TCNNF
Open the markets!! $MSOS $TCNNF $GTBIF
I went hard into Trulieve shares again. $TRUL $TCNNF. Adult use is gonna get back on the ballot in 2026 in Florida. They are a real business with real operations, not like the Canadian joke companies. Also: I’m Canadian
Sitting on 510 October contracts, $6 strike. Lots of TCNNF/GTBIF shares as well.
Not undervalued, but I know which ones will thrive and survive. GTBIF and TCNNF. The most prudently run and operated.
Cannabis stocks high risk high reward right now. MSOX, MSOS, TLRY, CGC, TCNNF, and CURLF. The first two being ETFs with the first being a 2x leveraged one. The middle two Canadian companies and the latter two American companies. This is not financial advice…
Agree with you. Tilray is a dumpster fire, but to be honest I prefer GTBIF and TCNNF as S3 plays
I think I broke the risk management part of my brain is broken….100% of portfolio is in weed stocks. TCNNF,GTI,MSOS, and MSOX I’ve been averaging down and pulling $ out of everything else since I got into this in 2021. Still 23% to break even overall. I’m VERY optimistic.
Sometimes recovery can sneak up on you. TCNNF is up 200% from the recent lows.
Was happy to scoop up several hundred more shares of TCNNF this morning on the dip
Wow, over $20M in inflows yesterday into MSOS and about $20M in cash still left to deploy. MSOS bought 500K+ shares of GTBIF and TCNNF. And 1M+ shares of VRNOF, CRLBF, TSNDF, CBSTF and. of course, CURLF. What a day. https://x.com/junglejava1/status/1960540896346112463?s=46&t=R3FbbhS_l0lFIJt2nBUUiA
I like TCNNF. MSOS is probably safer than TLRY. TLRY might have greater swing potential. It just depends on whether or not you like to gamble. Again, I'm a huge TCNNF fan. Got to be on fidelity to get it. It’s not on Robinhood. Good luck!
“Smoke If You Got 'Em Based on my accumulated research input, it is my view that Pres. Trump will shortly (and finally!) give cannabis rescheduling the green light. According to my contacts, the principal motivating factor is not the rationale presented by leading advocates who the President is close to (e.g. Weldon Angelos, Mike Tyson and industry influencers like Trulieve's (TCNNF) Kim Rivers and others) but rather the desire to embarrass the Democratic party who were unable to bring to ball over the goal line during the Biden Administration. The President, I have been told, also wants to gain favor from a specific population (and voting) sector. Frankly, after all these years I and others will take it anyway we can get it! I got chai recently by reestablishing my (MSOS) long. (I also own MSOS calls) Smoke if you got 'em. Position: Long MSOS common M and calls VS BY DOUG KASSAUG 25, 2025 7:00 AM EDT”
“Smoke If You Got 'Em Based on my accumulated research input, it is my view that Pres. Trump will shortly (and finally!) give cannabis rescheduling the green light. According to my contacts, the principal motivating factor is not the rationale presented by leading advocates who the President is close to (e.g. Weldon Angelos, Mike Tyson and industry influencers like Trulieve's (TCNNF) Kim Rivers and others) but rather the desire to embarrass the Democratic party who were unable to bring to ball over the goal line during the Biden Administration. The President, I have been told, also wants to gain favor from a specific population (and voting) sector. Frankly, after all these years I and others will take it anyway we can get it! I got chai recently by reestablishing my (MSOS) long. (I also own MSOS calls) Smoke if you got 'em. Position: Long MSOS common M and calls VS BY DOUG KASSAUG 25, 2025 7:00 AM EDT” https://pro.thestreet.com/dougs-daily-diary
$MSOS has bought millions of shares of $CURLF in the past few weeks while dumping hundreds of thousands of shares of other MSOs like $GTBIF and $TCNNF
GTBIF TCNNF CURLF JAZZ a pharmaceutical company that has several marijuana based drugs.
Fluent stock is still way underrated even though its shares are held more by insiders than any other MSO companies. Fluent shares: 36.43% held by insiders, 1.86% by institutions Compared to the top MSO companies. CURLF: 27.84% by insiders, 2.41% by institutions. TCNNF: 3.86% by insiders, 5.15% by institutions GTBIF: 1.86% by insiders, 14.24% by institutions. These figure are from Yahoo Finance.
TCNNF stands to gain absolutely nothing from rescheduling. They already write off their business expenses, and that's the only real benefit of rescheduling for multi-state operators. There still won't be any interstate commerce because of the FDA.
$MSOS calls - Cannabis rescheduling gaining crazy momentum. More news by the week! $GTBIF & $TCNNF long with shares.
Loaded up on $TCNNF and $GTBIF. $MSOS 510 contracts at $6 strike for late October. Looking for a gap fill back to $7-8 in a few weeks.
TCNNF and BLOZF are my pot plays.
I’ll be holding GTBIF and TCNNF because those are legitimate companies that don’t throw their shareholders under the bus every time they make a bad acquisition.
Also long TCNNF and GTBIF https://preview.redd.it/95vx986ymwif1.jpeg?width=1290&format=pjpg&auto=webp&s=3e7eef256f1b1e4ff92ec4cba45429b9d2e97d4c
GTBIF and TCNNF are my largest holdings and I've been happy with both so far. I think there will be bigger days ahead for GTBIF
GTI refusing to pump is hard to watch. Whats even more insane is that TCNNF is getting close to passing GTI in share price
$MSOS is going to run. Rescheduling imminent. $GTBIF $TCNNF
TCNNF - Trulieve, huge presence in Florida, Pennsylvania and Arizona.
My biggest position was TCNNF leading into the election. Took a 50% haircut when A3 failed, sold it all for around $7 USD mostly breaking even (six figures in gains evaporated overnight). Sat in SP 500 for most of the year, then rebuilt a position in GTBIF and TCNNF while $MSOS was under $3.00 in June/July and am still holding now
Ya most likely, I actually don't like TRUL at all and haven't for a long time. Should have listened to myself over and over prior to the election but I bought into the Florida rec' hype despite thinking it was a super long shot with the 60%. Definitely still kicking myself for that one. IMO TCNNF has been nothing but bad news since the Harvest merger.
Theres a ton of new people on this sub now that we are rallying again. But anyone thats been here day in day knows GTBIF is the goat, TCNNF being a second. If people are pushing Canadian companies they are most likely just returning with the hype